EDWARD VICTOR PROCHOWNIK
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD046934L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15208
Professional information
Dr. Edward V Prochownik, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
Pittsburgh Office
4401 Penn Ave STE 2000, Pittsburgh 15224
(412) 692-5325 (Phone), (412) 692-6076 (Fax)
Childrens Hematolgy Onclgy Clin
4401 Penn Ave STE 9, Pittsburgh 15224
(412) 692-5055 (Phone)
4401 Penn Ave STE 2000, Pittsburgh 15224
(412) 692-5325 (Phone), (412) 692-6076 (Fax)
Childrens Hematolgy Onclgy Clin
4401 Penn Ave STE 9, Pittsburgh 15224
(412) 692-5055 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2012, Pediatrics, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Pittsburgh Office
4401 Penn Ave STE 2000, Pittsburgh 15224
Childrens Hematolgy Onclgy Clin
4401 Penn Ave STE 9, Pittsburgh 15224
Magee-Womens Hospital of UPMC
300 Halket St, Pittsburgh 15213
4401 Penn Ave STE 2000, Pittsburgh 15224
Childrens Hematolgy Onclgy Clin
4401 Penn Ave STE 9, Pittsburgh 15224
Magee-Womens Hospital of UPMC
300 Halket St, Pittsburgh 15213
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1978
Childrens Hospital
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1978
Childrens Hospital
Edward V Prochownik, Pittsburgh PA
Specialties:
Pediatrician
Address:
4401 Penn Ave, Pittsburgh, PA 15224
3705 5Th Ave, Pittsburgh, PA 15213
3705 5Th Ave, Pittsburgh, PA 15213
Education:
University of Chicago, Pritzker School of Medicine - Doctor of Medicine
University of Chicago - Doctor of Philosophy
Children's Hospital Boston - Fellowship - Hematology and Oncology (Internal Medicine)
Children's Hospital Boston - Residency - Pediatrics
University of Chicago - Doctor of Philosophy
Children's Hospital Boston - Fellowship - Hematology and Oncology (Internal Medicine)
Children's Hospital Boston - Residency - Pediatrics
Board certifications:
American Board of Pediatrics Certification in Pediatrics, American Board of Pediatrics Sub-certificate in Pediatric Hematology/Oncology (Pediatrics)
Edward Prochownik, Pittsburgh PA
Work:
Children's Hospital of Pittsburgh
3705 5Th Ave, Pittsburgh, PA 15213 Childrens Hosp Of Pittsburgh Of Upmc
4401 Penn Ave, Pittsburgh, PA 15224 Children's Hospital of Pittsburgh
1 Childrens Hospital Dr, Pittsburgh, PA 15224
3705 5Th Ave, Pittsburgh, PA 15213 Childrens Hosp Of Pittsburgh Of Upmc
4401 Penn Ave, Pittsburgh, PA 15224 Children's Hospital of Pittsburgh
1 Childrens Hospital Dr, Pittsburgh, PA 15224
Pharmacologic Inhibition Of Myc Function
US Patent:
2004003, Feb 19, 2004
Filed:
Jun 12, 2003
Appl. No.:
10/459769
Inventors:
Edward Prochownik - Pittsburgh PA, US
Christine Giap - Pittsburgh PA, US
John Lazo - Pittsburgh PA, US
Xiaoying Yin - Chapel Hill NC, US
Christine Giap - Pittsburgh PA, US
John Lazo - Pittsburgh PA, US
Xiaoying Yin - Chapel Hill NC, US
International Classification:
A61K031/445, A61K031/427, A61K031/4245, A61K031/137
US Classification:
514/317000, 514/364000, 514/369000, 514/424000, 514/649000
Abstract:
The c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor, is frequently deregulated in human cancers. All known functions of c-Myc, including those pertaining to transformation, require that it heterodimerize with another HLH-ZIP protein, Max. Using a high throughput yeast-based assay, we identified seven low molecular weight substances that inhibit c-Myc-Max association. Each compound also prevented this interaction in vitro and inhibited the growth of c-Myc-expressing fibroblasts, although not of fibroblasts lacking c-Myc. Finally, short-term exposure of c-Myc over expressing fibroblasts to several of the compounds markedly reduced their in vivo tumorigenicity. These studies suggest that yeast-based assays can be used to identify inhibitors of protein-protein interactions and that these frequently function in mammalian cells. The signature specificities of each of the c-Myc-Max compounds identified here further suggest synergistic in vivo function.
Small Molecule Inhibitors Of Cancer Stem Cells
US Patent:
2010029, Nov 25, 2010
Filed:
May 6, 2010
Appl. No.:
12/775023
Inventors:
Edward V. Prochownik - Pittsburgh PA, US
John S. Lazo - Pittsburgh PA, US
John S. Lazo - Pittsburgh PA, US
International Classification:
A61K 31/52, A61K 31/353, A61P 35/00
US Classification:
5142634, 514456
Abstract:
A method of inhibiting a carcinoma in a subject, comprising administering to the subject at least one therapeutic agent that selectively targets carcinoma stem cells. Illustrative carcinoma stem cell-selective therapeutic agents include CGP74514A, rottlerin, and A-77636.
Cancer Stem Cell Immortalization
US Patent:
2011024, Oct 6, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/927225
Inventors:
Edward A. Prochownik - Pittsburgh PA, US
International Classification:
C12Q 1/68, C12N 5/095, C12N 5/10, C12N 15/85, C12Q 1/18, G01N 33/574
US Classification:
435 613, 435325, 4353201, 435 32, 435 723
Abstract:
The present invention relates to the preparation and use of immortalized cancer stem cells. The immortalized cancer stem cells of the invention may be used in assays to identify anti-cancer compounds as well as molecules critical to carcinogenesis. Further, cancer stem cells may be harvested from a patient and used, according to the invention, to select agents more likely to be effective in treating the cancer of that particular patient.
Low Molecular Weight Myc-Max Inhibitors
US Patent:
7872027, Jan 18, 2011
Filed:
Feb 16, 2007
Appl. No.:
11/707421
Inventors:
Steven J. Metallo - Silver Springs MD, US
Edward V. Prochownik - Pittsburgh PA, US
Edward V. Prochownik - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
Georgetown University - Washington DC
Georgetown University - Washington DC
International Classification:
A61K 31/427, A61K 31/445, C07D 277/08, C07D 417/02
US Classification:
514326, 546184, 546192, 546209, 548146, 548182, 548183, 514315, 514365, 514369
Abstract:
Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.
Linked Myc-Max Small Molecule Inhibitors
US Patent:
8637556, Jan 28, 2014
Filed:
Jan 15, 2010
Appl. No.:
13/144674
Inventors:
Steven J. Metallo - Silver Spring MD, US
Edward V. Prochownik - Pittsburgh PA, US
Ariele Viacava Follis - Memphis TN, US
Edward V. Prochownik - Pittsburgh PA, US
Ariele Viacava Follis - Memphis TN, US
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA
Georgetown University - Washington DC
Georgetown University - Washington DC
International Classification:
A61K 31/427, A61K 31/4245, C07D 277/04, C07D 413/02
US Classification:
514364, 514369, 548126, 548183, 435375
Abstract:
Provided herein are compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.